Association Between Benzodiazepine or Z-Drug Prescriptions and Drug-Related Poisonings Among Patients Receiving Buprenorphine Maintenance: A Case-Crossover Analysis
Publication: American Journal of Psychiatry
Abstract
Objective:
Persons with opioid use disorder who take benzodiazepines are at high risk for overdose. The objective of this study was to evaluate the association of benzodiazepine and Z-drug use with drug-related poisonings among patients receiving buprenorphine maintenance treatment.
Methods:
A case-crossover study design was used to analyze prescription claims among persons ages 12–64 with opioid use disorder who had buprenorphine prescriptions and had claims data in the IBM MarketScan databases (2006–2016), encompassing 14,213,075 person-days of observation time for 23,036 individuals who experienced drug-related poisoning. The exposures were buprenorphine prescriptions and benzodiazepine or Z-drug prescriptions, standardized as daily diazepam-equivalent milligram doses and separated by pharmacologic properties (short-acting or long-acting benzodiazepines, Z-drugs). The outcome of interest was nonfatal drug-related poisoning. Conditional logistic regression was used to evaluate variation in benzodiazepine or Z-drug and buprenorphine use between poisoning and nonpoisoning days.
Results:
Buprenorphine treatment days were associated with a nearly 40% reduction in the risk of poisoning events (odds ratio=0.63, 95% CI=0.60, 0.66) compared with nontreatment days, whereas benzodiazepine or Z-drug treatment days were associated with an 88% increase in the risk of such events (95% CI=1.78, 1.98). In stratified analyses by dose, we observed a 78% (95% CI=1.67, 1.88) and 122% (95% CI=2.03, 2.43) increase in poisonings associated with low-dose and high-dose benzodiazepine or Z-drug treatment days, respectively. High-dose, but not low-dose, benzodiazepine or Z-drug treatment was associated with increased poisonings in combination with buprenorphine cotreatment (odds ratio=1.64, 95% CI=1.39, 1.93), but this was lower than the odds risk associated with benzodiazepine or Z-drug treatment in the absence of buprenorphine (low-dose: odds ratio=1.69, 95% CI=1.60, 1.79; high-dose: odds ratio=2.23, 95% CI=2.04, 2.45).
Conclusions:
Increased risk of nonfatal drug-related poisoning is associated with benzodiazepine or Z-drug treatment in patients with opioid use disorder, but this risk is partially mitigated by buprenorphine treatment. Dose reduction of benzodiazepines or Z-drugs while maintaining buprenorphine treatment may provide the advantage of lowering drug-related poisoning risk.
Buprenorphine is an effective treatment for opioid use disorder, contributing to significant reductions in all-cause and opioid-associated mortality amid the current U.S. opioid epidemic (1). Among patients with opioid use disorder who are taking buprenorphine, benzodiazepine use is highly prevalent. Some studies have estimated that as many as 30% of patients with opioid use disorder who receive opioid maintenance treatment also receive benzodiazepine prescriptions (2), with more than one-third of these patients endorsing past-month problematic use of benzodiazepines (3). Although benzodiazepines are frequently prescribed for treatment of comorbid mood and anxiety disorders, which are common in this patient population, recent research has shed light on respiratory depression, overdose risk, and addictive potential associated with benzodiazepine use in patients taking opioids chronically, such as buprenorphine (4 –7). It is unclear whether the risks associated with benzodiazepine use outweigh the treatment benefits of buprenorphine.
The relationship between benzodiazepine use and buprenorphine treatment outcomes is poorly characterized. Existing observational studies that examined mortality risk associated with benzodiazepine prescriptions among patients with opioid use disorder have produced contradictory results (8 –10). While some findings suggest that benzodiazepines may enhance retention in buprenorphine maintenance treatment (4, 11), benzodiazepines have also been associated with increases in drug-related poisonings (11 –14), all-cause mortality (11), nonoverdose deaths (8), decreased retention in treatment (12, 15 –17), and accidental injury-related emergency department visits (5). To our knowledge, no studies have specifically examined potential additive or interactive effects between buprenorphine and benzodiazepines.
Another limitation of the current research base for benzodiazepine-related morbidity and mortality is that the different pharmacologic properties of sedative/hypnotics, such as half-life and potency, have seldom been explored (18). This is an important clinical and scientific gap, given that shorter-acting benzodiazepines, such as alprazolam, are thought to have higher addictive potential than longer-acting medications, such as clonazepam (6, 19). In fact, previous studies of populations without opioid use disorder have shown significant intra-benzodiazepine variation in health outcomes; for example, certain benzodiazepines appear to be associated with greater injury risk in the elderly than others (18). Additionally, little research has investigated drug-related poisoning associated with selective benzodiazepine receptor modulators (Z-drugs: zolpidem, zaleplon, and eszopiclone). These medications have increasingly been found to have a spectrum of adverse effects similar to that for benzodiazepines, with similar dose-response effects on all-cause mortality in the general population (20, 21). Because studies to date have relied on relatively small numbers of benzodiazepine users, they have precluded examination of how drug subclasses (e.g., short-acting compared with long-acting benzodiazepines, Z-drugs) or dosing regimens affect opioid use disorder outcomes.
In light of the research gap on opioid use disorder outcomes among patients taking both buprenorphine and benzodiazepines or Z-drugs, we used the IBM MarketScan Research Databases (2006–2016; IBM, Armonk, N.Y.) in the present study to quantify odds of nonfatal drug-related poisoning (including overdoses) associated with benzodiazepine or Z-drug use in patients with opioid use disorder; to determine whether benzodiazepine or Z-drug use improves, nullifies, or reverses the protective effect of buprenorphine in patients with opioid use disorder; and to evaluate whether different sedative/hypnotic subtypes (e.g., long-acting compared with short-acting agents and Z-drugs) correspond to different poisoning risks.
Methods
Data Set and Study Subjects
We used pharmaceutical claims data on 304,676 individuals, ages 12–64, in the IBM MarketScan Commercial and Multi-State Medicaid Databases who received buprenorphine treatment for opioid use disorder (Figure 1). The data, spanning from January 1, 2006, to December 31, 2016, represent claims for insured active employees, early (non-Medicare) retirees, and dependents insured by employer-sponsored plans, as well as Medicaid insurance holders, spanning all 50 states (22). Details on data extraction are summarized in the Methods section in the online supplement . Because all data were de-identified, our analysis was exempt from human subjects review by the institutional review board at Washington University, St. Louis.
Individuals ages 12 to 64 with insurance claims indicating an opioid use disorder diagnosis, at least one buprenorphine prescription, and at least one nonfatal drug-related poisoning were included for analysis. Buprenorphine prescriptions were defined by associated diagnostic codes selected using established methods (22) (for the list of codes, see Table S1 in the online supplement ). We included persons who had periods of buprenorphine-free treatment as long as they received the medication at another time point. Buprenorphine use was characterized in terms of strength, quantity, and days of supply in order to calculate a daily milligram dose. This was further stratified into daily buprenorphine doses >12 mg and ≤12 mg, given previous analyses suggesting differences in treatment retention associated with this dose (23). Because each individual serves as his or her own control in case-crossover designs, all individuals in the sample must experience the outcome at least once. Therefore, we excluded all individuals who did not experience a drug-related poisoning.
Study Design
We used a case-crossover study design that exploited within-subject variation in exposure and outcome, which addresses unobserved time-invariant confounding by allowing each individual to serve as his or her own control. Units of observation were person-days, denoting days during which patients were enrolled in a health insurance plan. Case periods were days when a patient experienced nonfatal drug-related poisonings. Control periods were nearby days without poisoning events (24, 25). We characterized each person-day of observation by the presence or absence of benzodiazepine or Z-drug treatment and the presence or absence of buprenorphine treatment. Each study subject could have multiple poisoning events as long as these events fell within the interval of ≤365 days before and after the index poisoning (Figure 2). Individuals with fewer observation days on either side of the index event were included with missing days treated as censored. We evaluated study subjects during a time period up to 1 year before and the year after their first drug-related poisoning (index date), thus limiting subjects to a maximum of 2-year periods of observation to reduce heterogeneity in observation time per person. We included periods both before and after the index poisoning in order to define the poisoning as a repeatable event, allowing for the inclusion of time as a covariate (25, 26). Thus, the unit of analysis was days, stratified within persons, and the comparison of interest was drug exposure status concurrent with drug-related poisoning (case period) compared with exposure status during referent periods when poisoning events did not occur (control period).
FIGURE 2. Overview of the case-crossover design analyzing patients with opioid use disorder with a drug-related poisoninga
a Treatment days during which an individual received a medication, such as a benzodiazepine or buprenorphine, that culminated in drug-related poisoning (hatched boxes) are compared with days that did not coincide with a poisoning event for the same medication (shaded boxes). An observation period spanning up to 1 year (at most) before and after the index poisoning was used. Consequently, each individual could potentially contribute multiple drug-related poisoning events to the final analysis, as long as such events were within a maximum of 1 year before and 1 year after the index poisoning event. For individual 1, five treatment periods are shown, two of which culminated in a drug-related poisoning. This contrasts with individual 2, who had two treatment periods, only one of which culminated in a drug-related poisoning. Individual 2 had three drug-related poisonings, two of which were not preceded by medication treatment. Individuals 3 and 4 notably did not have any treatment periods culminating in drug-related poisoning.
Given their high prevalence in clinical practice and overlapping indications with benzodiazepines, selective serotonin reuptake inhibitors (SSRIs) (sertraline, fluoxetine, escitalopram, and citalopram) were included in our conditional logistic models as an active comparator analysis. This is a validated approach employed by previous investigators (27) to control for unobserved confounding. In other words, the SSRI term assesses whether underlying conditions for which patients were receiving benzodiazepines or Z-drugs contributed to drug-related poisonings.
Ascertainment of Outcomes and Exposures
The primary outcome was nonfatal drug-related poisonings (including overdoses) (Figure 2). Controls were adjacent person-days when a poisoning event did not occur. Poisonings were defined using ICD codes and Healthcare Common Procedure Coding System codes for naloxone reversal. In accordance with guidelines compiled by the Centers for Disease Control and Prevention consensus recommendations for poisoning surveillance (28), the codes we employed encompassed not only opioids but also alcohol, benzodiazepines, psychotropic medication, and overdose with other substances (see Table S1 in the online supplement ). This was intended to capture conditions commonly associated with chronic drug misuse, as well as to avoid misclassification bias and underestimation of overdose risks. We searched all emergency department visits, outpatient ambulatory visits, and hospitalizations for relevant diagnostic codes (28).
The primary exposure was benzodiazepine or Z-drug prescriptions, ascertained through pharmacy files. A person was assumed to be exposed if he or she was covered by a prescription for a drug on a given day. We characterized initial benzodiazepine, Z-drug, and buprenorphine prescriptions in terms of strength, quantity dispensed, and days of supply. To standardize the daily dose, we calculated the strength of each benzodiazepine or Z-drug in terms of total diazepam-equivalent milligrams (29) using known pharmacologic conversion factors (see Table S2 in the online supplement ) (30 –32). We calculated a daily diazepam-equivalent dose by multiplying the number supplied by strength (in diazepam-equivalent milligrams) and dividing by days of supply. Benzodiazepine and Z-drug dosage was stratified into high-dose (diazepam-equivalent-mg dose >30 mg) and low-dose (≤30 mg) based on established thresholds (33). Benzodiazepine exposure was categorized by the duration of action, namely, short-acting (half-life ≤24 hours) or long-acting (half-life >24 hours), guided by established classifications (6). Specific classifications of benzodiazepines and Z-drugs, based on previously published definitions, are presented in Table S2 in the online supplement (34, 35).
We also collected data on age, sex, relationship of patient to the primary beneficiary, and insurance status. Because cases were self-matched in a case-crossover design, our models did not warrant adjustment for time-invariant measured confounders (e.g., sex and race).
Statistical Analysis
Analyses were conducted on a day-level data set in which each medication coverage date was identified. All analyses were conducted using SAS, version 9.4 (SAS Institute, Cary N.C.). Before evaluating variation in medication exposure between case and control days, we calculated descriptive statistics for the primary analytical sample (i.e., patients who had nonfatal drug-related poisonings). To compare the characteristics of opioid use disorder treatment between patients with and without poisoning events, we obtained a random sample of persons who never experienced poisonings and compared descriptive statistics between them and those who had poisoning events (see the Methods section and Tables S3 and S4 in the online supplement ).
To evaluate the effect of medication exposure, we estimated conditional logistic regression models stratified by subject and modeled the risk of poisoning as a function of drug exposure by days with or without treatment. We first built a crude model containing benzodiazepine or Z-drug prescription status as the only predictor variable. We then built additional models that included predictor variables for both benzodiazepine or Z-drug and buprenorphine prescription status. Simultaneous inclusion of benzodiazepines or Z-drugs and buprenorphine permitted us to model additive or interactive effects of benzodiazepines or Z-drugs and buprenorphine in association with drug-related poisonings. SSRIs were included in our models as an active comparator analysis. Subgroup analyses were conducted to assess the effect of buprenorphine treatment days, compared with days without treatment, on drug-related poisoning among patients who received benzodiazepine or Z-drug prescriptions and those who did not. Controls for both calendar time and time from index poisoning were included using cubic spline methods, described in detail in the Methods section in the online supplement . Several sensitivity analyses were conducted to evaluate the possibility of persistent user bias and to assess the robustness of our findings to alternative time samplings (see Figure S1, the Methods section, and Table S5 in the online supplement ).
Results
Study Sample and Treatment Characteristics
Of 304,676 individuals ages 12–64 with an opioid use disorder diagnosis, prescription drug coverage, and at least one opioid use disorder claim during the period of enrollment, we excluded individuals without drug-related poisonings, individuals who never received medication for opioid use disorder, and individuals without days of naltrexone and methadone treatment and days of observation outside a maximum of a 1-year period before and after the index poisoning (Figure 1). Our final analytic sample comprised 23,036 patients (mean age, 30 years [SD=12.15]; 51% male; mean observation time, 299 days [SD=107.88]), spanning 14,213,075 person-days of insurance coverage (Table 1). A total of 2,210,927 person-days (15.6%) entailed claims for buprenorphine (mean daily dose, 15.4 mg [SD=7.31]). A total of 1,968,944 person-days (13.9%) entailed claims for benzodiazepines or Z-drugs, of which 474,181 person-days entailed concurrent buprenorphine treatment. We calculated the mean daily dose of any benzodiazepine or Z-drug to be 23.4 diazepam-milligram equivalents and the mean daily dose for short-acting benzodiazepines, long-acting benzodiazepines, and Z-drugs to be 25.3, 31.3, and 4.9 diazepam-milligram equivalents, respectively (Table 2).
| Characteristic | ||
|---|---|---|
| N | % | |
| Buprenorphine use | 16,451 | 71.41 |
| Low-dose (≤12 mg daily) | 9,469 | 41.11 |
| High-dose (>12 mg daily) | 11,690 | 50.75 |
| Benzodiazepine or Z-drug use | 12,890 | 55.96 |
| Benzodiazepine use excluding Z-drugs | 11,839 | 51.39 |
| Low-dose (≤30 diazepam-equivalent mg daily) | 10,356 | 44.96 |
| High-dose (>30 diazepam-equivalent mg daily) | 5,227 | 22.69 |
| Short-acting benzodiazepine use | 9,292 | 40.34 |
| Alprazolam | 6,210 | 26.96 |
| Lorazepam | 4,433 | 19.24 |
| Oxazepam | 130 | 0.56 |
| Triazolam | 248 | 1.08 |
| Estazolam | 19 | 0.08 |
| Temazepam | 1,127 | 4.89 |
| Midazolam | 47 | 0.2 |
| Long-acting benzodiazepine use | 6,660 | 28.91 |
| Clonazepam | 3,885 | 16.86 |
| Diazepam | 3,612 | 15.68 |
| Chlordiazepoxide | 206 | 0.89 |
| Clobazam | 1 | 0 |
| Flurazepam | 33 | 0.14 |
| Quazepam | 2 | 0.01 |
| Z-drug use | 5,068 | 22 |
| Zolpidem | 4,640 | 20.14 |
| Eszopiclone | 1,025 | 4.45 |
| Zaleplon | 216 | 0.94 |
| Methadone use | 420 | 1.82 |
| Naltrexone use | 1,449 | 6.29 |
| Naltrexone extended-release use | 746 | 3.24 |
| Selective serotonin reuptake inhibitor use | 10,286 | 44.65 |
| Mean | SD | |
| Age (years) | 30.05 | 12.15 |
| Year of birth | 1980 | |
| Days of observation | 298.73 | 107.88 |
| N | % | |
| Male | 11,713 | 50.85 |
| Relationship of patient to primary beneficiary | ||
| Employee | 4,345 | 28.30 |
| Spouse | 3,746 | 24.40 |
| Child or other | 7,263 | 47.30 |
| Medicaid | 7,682 | 33.35 |
a
The data represent opioid use disorder treatment characteristics at the individual subject level among patients with a history of drug-related poisoning during the study’s observation window (up to 1 year before and 1 year after the index poisoning event). While all study subjects had prescriptions for buprenorphine in the IBM MarketScan database (a requirement for inclusion in the final analytic sample), only 71% had buprenorphine claims during the time period up to 1 year before and 1 year after the index poisoning event.
| Characteristic | N | % |
|---|---|---|
| Treatment days marked by drug-related poisoning | 26,243 | 0.18 |
| Days treated with buprenorphine | 2,210,927 | 15.56 |
| Dose (mean±SD) | 15.44 | 7.31 |
| Low-dose (≤12 mg daily) | 758,261 | 5.33 |
| High-dose (>12 mg daily) | 1,367,893 | 9.62 |
| Days treated with selective serotonin reuptake inhibitors | 1,715,489 | 12.07 |
| Days treated with benzodiazepines or Z-drugs | 2,493,800 | 17.55 |
| Dose (diazepam-equivalent mg daily) (mean±SD) | 23.39 | 25.88 |
| Days treated with benzodiazepines excluding Z-drugs | 1,968,944 | 13.85 |
| Dose (diazepam-equivalent mg daily) (mean±SD) | 27.58 | 26.98 |
| Low-dose (≤30 diazepam-equivalent mg daily) | 1,453,110 | 10.22 |
| High-dose (>30 diazepam-equivalent mg daily) | 515,834 | 3.63 |
| Days treated with short-acting benzodiazepines | 1,584,424 | 11.15 |
| Dose (diazepam-equivalent mg daily) | 25.33 | 20.53 |
| Days treated with long-acting benzodiazepines | 452,820 | 3.19 |
| Dose (diazepam-equivalent mg daily) | 31.28 | 38.10 |
| Days treated with Z-drugs | 825,610 | 5.81 |
| Dose (diazepam-equivalent mg daily) (mean±SD) | 4.88 | 1.24 |
| Concurrent use of buprenorphine or benzodiazepines or Z-drugs | ||
| Days without buprenorphine or benzodiazepine or Z-drug treatment | 9,982,529 | 70.23 |
| Days treated with benzodiazepines or Z-drugs only | 2,019,619 | 14.21 |
| Days treated with buprenorphine only | 1,736,746 | 12.22 |
| Days treated with concurrent buprenorphine and benzodiazepines or Z-drugs | 474,181 | 3.34 |
a
Data are presented as Ns and percentages except as otherwise noted. Among all individuals with a history of drug-related poisoning during the study’s observation window (1 year before and 1 year after the index poisoning event), the number of person-days for which insurance claims were filed for medication treatment was calculated. Because the data in this table do not represent the individual subject level, it was possible for an individual subject to contribute multiple person-days.
Benzodiazepines or Z-Drugs and Drug-Related Poisonings
Buprenorphine treatment days were associated with 37% lower odds of drug-related poisoning (95% CI=0.60, 0.66) compared with nontreatment days, whereas odds of poisoning increased 81% on days when patients were treated with benzodiazepines or Z-drugs (95% CI=1.73, 1.91; model 1) (Table 3). When we evaluated benzodiazepines and Z-drugs separately, Z-drug treatment days were associated with increased odds of poisoning events (odds ratio=1.29, 95% CI=1.19, 1.39), but this was notably lower than the odds associated with benzodiazepine treatment days (odds ratio=1.88, 95% CI=1.78, 1.98; model 2). We found no association between SSRI treatment days and drug-related poisonings (odds ratio=0.95, 95% CI=0.90, 1.00; model 3). We observed no difference in the magnitude of protective effect against poisoning conferred by buprenorphine treatment days when conducting stratified analyses of patients who used benzodiazepines or Z-drugs (odds ratio=0.64, 95% CI=0.60, 0.69, model 4) and those who never used benzodiazepines or Z-drugs during the study’s observation period (odds ratio=0.64, 95% CI=0.59, 0.69; model 5).
| Variable | Odds Ratio | 95% CI |
|---|---|---|
| Model 1 | ||
| Buprenorphine | 0.63 | 0.60, 0.66 |
| Any benzodiazepine or Z-drug | 1.81 | 1.73, 1.91 |
| Model 2 | ||
| Buprenorphine | 0.63 | 0.60, 0.67 |
| Benzodiazepines, excluding Z-drugs | 1.88 | 1.78, 1.98 |
| Z-drugs | 1.29 | 1.19, 1.39 |
| Model 3 | ||
| Buprenorphine | 0.63 | 0.60, 0.67 |
| Benzodiazepines, excluding Z-drugs | 1.88 | 1.79, 1.99 |
| Z-drugs | 1.29 | 1.19, 1.40 |
| Selective serotonin reuptake inhibitors | 0.95 | 0.90, 1.00 |
| Model 4 | ||
| Buprenorphine (among benzodiazepine or Z-drug users) | 0.64 | 0.60, 0.69 |
| Model 5 | ||
| Buprenorphine (among benzodiazepine or Z-drug nonusers) | 0.64 | 0.59, 0.69 |
| Model 6 | ||
| Buprenorphine | 0.63 | 0.60, 0.66 |
| Short-acting benzodiazepines | 1.86 | 1.75, 1.97 |
| Long-acting benzodiazepines | 1.68 | 1.54, 1.83 |
| Z-drugs | 1.29 | 1.19, 1.39 |
| Model 7 | ||
| Buprenorphine | 0.63 | 0.60, 0.66 |
| Low-dose benzodiazepines | 1.78 | 1.67, 1.88 |
| High-dose benzodiazepines | 2.22 | 2.03, 2.43 |
| Z-drugs | 1.29 | 1.19, 1.39 |
| Model 8 | ||
| Buprenorphine | 0.64 | 0.62, 0.67 |
| Any benzodiazepine or Z-drug, low-dose | 1.86 | 1.77, 1.95 |
| Any benzodiazepine or Z-drug, high-dose | 2.53 | 2.35, 2.73 |
| Model 9 | ||
| Low-dose buprenorphine | 0.62 | 0.57, 0.67 |
| High-dose buprenorphine | 0.63 | 0.59, 0.67 |
| Low-dose benzodiazepines | 1.78 | 1.68, 1.88 |
| High-dose benzodiazepines | 2.22 | 2.03, 2.43 |
| Z-drugs | 1.29 | 1.19, 1.39 |
| Model 10 | ||
| Buprenorphine only | 0.61 | 0.58, 0.65 |
| Benzodiazepine or Z-drug, low-dose (plus buprenorphine) | 1.11 | 1.00, 1.23 |
| Benzodiazepine or Z-drug, high-dose (plus buprenorphine) | 1.64 | 1.39, 1.93 |
| Benzodiazepine or Z-drug, low-dose (no buprenorphine) | 1.69 | 1.60, 1.79 |
| Benzodiazepine or Z-drug, high-dose (no buprenorphine) | 2.23 | 2.04, 2.45 |
a
Low-dose benzodiazepines are ≤30 diazepam-equivalent milligrams daily; high-dose benzodiazepines are >30 diazepam-equivalent milligrams daily; low-dose Z-drugs are ≤30 diazepam-equivalent milligrams daily; high-dose Z-drugs are >30 diazepam-equivalent milligrams daily; low-dose buprenorphine is ≤12 mg/day; and high-dose buprenorphine is >12 mg/day.
Subgroup and Sensitivity Analyses
We stratified benzodiazepines by mechanism and observed similarly elevated odds of drug-related poisoning for short-acting benzodiazepine treatment days (odds ratio=1.86, 95% CI=1.75, 1.97; model 6) and long-acting benzodiazepine treatment days (odds ratio=1.68, 95% CI=1.54, 1.83; model 6). When we stratified benzodiazepines by low and high doses, we found the increases in the odds of a poisoning event to be 78% (95% CI=1.67, 1.88; model 6) and 122% (95% CI=2.03, 2.43; model 7), respectively. To assess whether this dose-response relationship remained significant across all sedative/hypnotic drugs, we grouped benzodiazepines and Z-drugs together and stratified them into low-dose and high-dose strata, observing a similar pattern of increased poisoning odds associated with dose (low-dose: odds ratio=1.86, 95% CI=1.77, 1.79; high-dose: odds ratio=2.53, 95% CI=2.35, 2.73; model 8). In contrast to benzodiazepines, we found similar protective effects of buprenorphine irrespective of the daily dose threshold (low-dose: odds ratio=0.62, 95% CI=0.57, 0.67; high-dose: odds ratio=0.63, 95% CI=0.59, 0.67; model 9).
Interaction Between Benzodiazepines or Z-Drugs and Buprenorphine
The odds of drug-related poisoning associated with benzodiazepine or Z-drug use, stratified by benzodiazepine or Z-drug dose and buprenorphine course, are presented in Table 3 (model 10). Stratification on these variables allowed for observation of possible interaction effects between benzodiazepine or Z-drug dose and buprenorphine use. For high-dose benzodiazepines or Z-drugs, poisoning odds associated with buprenorphine course were higher than would have been expected based on the assumption of additive risks (Wald χ2=4.02, p=0.045). Odds ratios associated with low-dose and high-dose benzodiazepine or Z-drug course with buprenorphine use were 1.11 (95% CI=1.00, 1.23) and 1.64 (95% CI=1.39, 1.93), respectively. Notably, these effects were lower than those for low-dose and high-dose benzodiazepines or Z-drugs in the absence of buprenorphine (low-dose: odds ratio=1.69, 95% CI=1.60, 1.79; high-dose: odds ratio=2.23, 95% CI=2.04, 2.45, respectively). In other words, individuals with opioid use disorder taking both buprenorphine and benzodiazepines or Z-drugs had a lower net risk of poisoning than those taking benzodiazepines or Z-drugs without buprenorphine.
Discussion
In this study, we used the IBM MarketScan databases to analyze nonfatal drug-related poisoning (including overdose events) associated with specific benzodiazepines or Z-drugs and dosing regimens in patients with opioid use disorder. Even though buprenorphine treatment days conferred a nearly 40% reduction in poisonings, benzodiazepine or Z-drug treatment days corresponded to a near-doubling in poisoning risk. While individuals taking both buprenorphine and benzodiazepines or Z-drugs were at elevated risk of poisoning, they still had a lower net risk than those taking benzodiazepines or Z-drugs without buprenorphine. We found no association between SSRIs and drug-related poisoning, making it less likely that underlying conditions for which patients were receiving benzodiazepines or Z-drugs contributed to overdoses. Additionally, we found no dose dependence for the association between buprenorphine and poisoning risk.
Our findings may have significant implications for clinical practice. First, our results show a clear dose-dependent pattern of worsened overdose-related outcomes associated with benzodiazepine or Z-drug use, indicating that among patients with opioid use disorder for whom benzodiazepine or Z-drug cessation is risky, lower doses and shorter treatment duration of sedative/hypnotics may reduce risk. Second, we found slightly lower risk with long-acting benzodiazepines compared with short-acting benzodiazepines and substantially lower risk associated with Z-drugs compared with either long- or short-acting benzodiazepines, which may be related to lower mean standardized dosages observed for Z-drugs. Overall, these results suggest that switching benzodiazepine users from short-acting to long-acting agents or to Z-drugs may hold promise in lowering overdose risk.
Importantly, buprenorphine’s beneficial effect was observed among both benzodiazepine or Z-drug users and nonusers. This is an important finding because the safety of benzodiazepine or Z-drug use among buprenorphine users has been a topic of contentious debate in the past, leading to restrictions on buprenorphine treatment among benzodiazepine users that were later reversed by the U.S. Food and Drug Administration (4, 36). Our results demonstrate that even though benzodiazepines and Z-drugs may increase drug-related poisonings, buprenorphine’s protective effect is not eliminated by benzodiazepine or Z-drug treatment. Overall, our findings suggest that for patients taking both benzodiazepines or Z-drugs and buprenorphine, dose reduction of benzodiazepines or Z-drugs—while maintaining buprenorphine treatment—may have the advantage of decreasing overdoses associated with both benzodiazepines and the benzodiazepine-buprenorphine interaction. Because previous studies have found benzodiazepines to be associated with improved treatment retention in patients receiving buprenorphine (4, 11), dose reduction of benzodiazepines or Z-drugs may be preferable to abrupt cessation.
There are several limitations of this study. First, despite use of an active comparator and case-crossover design, we cannot exclude the possibility of residual confounding by indication. For example, benzodiazepines may constitute a proxy for underlying anxiety symptoms that lead to sedative/hypnotic prescriptions, substance use, and overdose, as opposed to directly contributing to poisoning. Unmeasured exposures, such as illicit substances and nonprescribed benzodiazepines, have commonly been noted in the opioid user population (37) and warrant further investigation. Second, secular time trends in exposure and outcome may introduce confounding into case-crossover designs (24, 25). We cannot rule out the possibility of unmeasured time-varying factors associated with drug-related poisoning and benzodiazepine or Z-drug exposure. Mitigating this, we made efforts to control for temporal variation and reduce heterogeneity in observation time per person using calendar time and time from event as a covariate and restricting study subjects to a maximum of 2-year periods of observation bracketing the index event. In addition to an active comparator analysis, we used bidirectional sampling (before and after index poisoning), which has been found to reduce overlap bias resulting from control period selection as a function of event times (25).
In addition, our study is limited by its focus on nonfatal drug-related poisonings as opposed to poisoning deaths. While our reliance on nonfatal poisoning allows for the creation of a more robust clinical risk profile that can be used to prevent fatal cases, further research evaluating the effect of benzodiazepine or Z-drug use on overdose deaths is warranted in light of our findings. Additionally, although the MarketScan data comprise a large, nationally representative sample with strong longitudinal follow-up at the patient level, the database is limited by measurement error, insofar as medication coverage does not always reflect the actual dose consumed. The generalizability of the MarketScan data is also limited to insured patients with observed drug-related poisonings. Our findings may not be generalizable to lower-risk patients who did not experience poisoning events within the study observation period.
A key strength of our study was its use of a case-crossover approach to harness within-person variation (i.e., individuals serving as their own controls) and to estimate the degree to which poisonings were reduced on days when patients were taking benzodiazepines or Z-drugs, as opposed to nontreatment days. Because each patient acted as his or her own control, we reduced the selection and sampling bias that would result from recruitment of different case and control subjects in conventional observational study designs. This also allowed us to examine the relationship between common exposures and less common acute outcomes, such as overdoses (18, 38, 39). Furthermore, this strategy allowed us to investigate subtle changes in exposure (i.e., variation by benzodiazepine or Z-drug dose and subtype) that may result in poisoning (18). We also used SSRIs as an active comparator to control for unobserved confounders and to serve as a proxy for underlying conditions leading to benzodiazepine prescriptions, given their overlapping indications with benzodiazepines and no known association with drug-related poisoning or mortality in adults. The lack of association between SSRI prescriptions and poisoning is notable, suggesting that increased odds of poisoning following receipt of a benzodiazepine prescription is more attributable to benzodiazepines than to underlying conditions leading to a prescription for a benzodiazepine or an SSRI. Finally, our findings are pharmacologically informed, because we used the high statistical power of the MarketScan database to identify subgroups of patients receiving buprenorphine who may have been at elevated risk of treatment failure, such as those taking short-acting or higher-potency benzodiazepines.
Conclusions
Patients with opioid use disorder who are treated with buprenorphine have double the odds of a drug-related poisoning when benzodiazepines or Z-drugs are coprescribed, with short-acting and high-dose benzodiazepines conferring additional risk. Buprenorphine remains protective against overdose in this high-risk population. Our findings contribute to emerging evidence that patients with opioid use disorder who receive buprenorphine may benefit from cessation or dose reduction of benzodiazepines or Z-drugs while remaining on buprenorphine.
Footnote
The authors thank Dr. Nuri Farber and the Psychiatry Residency Research Education Program of Washington University, St. Louis. The authors also thank John Sahrmann and the Center for Administrative Data Research (CADR) at Washington University for assistance with data acquisition, management, and storage. CADR is supported in part by the Washington University Institute of Clinical and Translational Sciences via grants UL1 TR002345 (from the National Center for Advancing Translational Sciences of NIH) and R24 HS19455 (from the Agency for Healthcare Research and Quality).
Supplementary Material
File (appi.ajp.2020.20081174.ds001.pdf)
- View/Download
- 399.24 KB
References
1.
Larochelle MR, Bernson D, Land T, et al : Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study. Ann Intern Med 2018 ; 169 : 137 – 145
2.
Bramness JG, Kornør H : Benzodiazepine prescription for patients in opioid maintenance treatment in Norway. Drug Alcohol Depend 2007 ; 90 : 203 – 209
3.
Lavie E, Fatséas M, Denis C, et al : Benzodiazepine use among opiate-dependent subjects in buprenorphine maintenance treatment: correlates of use, abuse and dependence. Drug Alcohol Depend 2009 ; 99 : 338 – 344
4.
Park TW, Larochelle MR, Saitz R, et al : Associations between prescribed benzodiazepines, overdose death and buprenorphine discontinuation among people receiving buprenorphine. Addiction 2020 ; 115 : 924 – 932
5.
Schuman-Olivier Z, Hoeppner BB, Weiss RD, et al : Benzodiazepine use during buprenorphine treatment for opioid dependence: clinical and safety outcomes. Drug Alcohol Depend 2013 ; 132 : 580 – 586
6.
Soyka M : Treatment of benzodiazepine dependence. N Engl J Med 2017 ; 376 : 1147 – 1157
7.
White JM, Irvine RJ : Mechanisms of fatal opioid overdose. Addiction 1999 ; 94 : 961 – 972
8.
Abrahamsson T, Berge J, Öjehagen A, et al : Benzodiazepine, z-drug and pregabalin prescriptions and mortality among patients in opioid maintenance treatment: a nation-wide register-based open cohort study. Drug Alcohol Depend 2017 ; 174 : 58 – 64
9.
Franklyn AM, Eibl JK, Gauthier G, et al : The impact of benzodiazepine use in patients enrolled in opioid agonist therapy in Northern and rural Ontario. Harm Reduct J 2017 ; 14 : 6
10.
Park TW, Saitz R, Ganoczy D, et al : Benzodiazepine prescribing patterns and deaths from drug overdose among US veterans receiving opioid analgesics: case-cohort study. BMJ 2015 ; 350 : h2698
11.
Macleod J, Steer C, Tilling K, et al : Prescription of benzodiazepines, z-drugs, and gabapentinoids and mortality risk in people receiving opioid agonist treatment: observational study based on the UK Clinical Practice Research Datalink and Office for National Statistics death records. PLoS Med 2019 ; 16 : e1002965
12.
Weinstein ZM, Cheng DM, Quinn E, et al : Psychoactive medications and disengagement from office based opioid treatment (OBOT) with buprenorphine. Drug Alcohol Depend 2017 ; 170 : 9 – 16
13.
Sansone RA, Sansone LA : Buprenorphine treatment for narcotic addiction: not without risks. Innov Clin Neurosci 2015 ; 12 : 32 – 36
14.
Häkkinen M, Launiainen T, Vuori E, et al : Benzodiazepines and alcohol are associated with cases of fatal buprenorphine poisoning. Eur J Clin Pharmacol 2012 ; 68 : 301 – 309
15.
Fareed A, Eilender P, Ketchen B, et al : Factors affecting noncompliance with buprenorphine maintenance treatment. J Addict Med 2014 ; 8 : 345 – 350
16.
Ferri M, Finlayson AJ, Wang L, et al : Predictive factors for relapse in patients on buprenorphine maintenance. Am J Addict 2014 ; 23 : 62 – 67
17.
Lee SC, Klein-Schwartz W, Doyon S, et al : Comparison of toxicity associated with nonmedical use of benzodiazepines with buprenorphine or methadone. Drug Alcohol Depend 2014 ; 138 : 118 – 123
18.
Tamblyn R, Abrahamowicz M, du Berger R, et al : A 5-year prospective assessment of the risk associated with individual benzodiazepines and doses in new elderly users. J Am Geriatr Soc 2005 ; 53 : 233 – 241
19.
Ait-Daoud N, Hamby AS, Sharma S, et al : A review of alprazolam use, misuse, and withdrawal. J Addict Med 2018 ; 12 : 4 – 10
20.
Gunja N : The clinical and forensic toxicology of Z-drugs. J Med Toxicol 2013 ; 9 : 155 – 162
21.
Weich S, Pearce HL, Croft P, et al : Effect of anxiolytic and hypnotic drug prescriptions on mortality hazards: retrospective cohort study. BMJ 2014 ; 348 : g1996
22.
Mintz CM, Presnall NJ, Sahrman JM, et al : Age disparities in six-month treatment retention for opioid use disorder. Drug Alcohol Depend (Epub ahead of print June 18, 2020)
23.
Barnett PG, Rodgers JH, Bloch DA : A meta-analysis comparing buprenorphine to methadone for treatment of opiate dependence. Addiction 2001 ; 96 : 683 – 690
24.
Allison P (ed): Fixed effects regression methods in SAS. San Francisco, 2006
25.
Mittleman MA, Mostofsky E : Exchangeability in the case-crossover design. Int J Epidemiol 2014 ; 43 : 1645 – 1655
26.
Allison P, Christakis NA : Fixed-effects methods for the analysis of nonrepeated events. Sociol Methodol 2006 ; 36 : 155 – 172
27.
Patorno E, Glynn RJ, Levin R, et al : Benzodiazepines and risk of all cause mortality in adults: cohort study. BMJ 2017 ; 358 : j2941
28.
Prescription drug overdose data and statistics: guide to ICD9 and ICD10 codes related to poisoning and pain, 2013. https://www.cdc.gov/drugoverdose/pdf/pdo_guide_to_icd-9-cm_and_icd-10_codes-a.pdf
29.
Sheehy O, Zhao JP, Bérard A : Association between incident exposure to benzodiazepines in early pregnancy and risk of spontaneous abortion. JAMA Psychiatry 2019
30.
Ashton H: Ashton manual: benzodiazepine equivalence table, 2007. https://www.benzo.org.uk/manual
31.
Howard P, Twycross R, Shuster J, et al : Benzodiazepines. J Pain Symptom Manage 2014 ; 47 : 955 – 964
32.
Sadock BJ, Sadock VA, Ruiz P : Kaplan and Sadock’s Comprehensive Textbook of Psychiatry. Philadelphia, Lippincott Williams and Wilkins, 2009
33.
Liebrenz M, Schneider M, Buadze A, et al : High-dose benzodiazepine dependence: a qualitative study of patients’ perceptions on initiation, reasons for use, and obtainment. PLoS One 2015 ; 10 : e0142057
34.
Gorevski E, Bian B, Kelton CM, et al : Utilization, spending, and price trends for benzodiazepines in the US Medicaid program: 1991–2009. Ann Pharmacother 2012 ; 46 : 503 – 512
35.
Bushnell GA, Stürmer T, Gaynes BN, et al : Simultaneous antidepressant and benzodiazepine new use and subsequent long-term benzodiazepine use in adults with depression, United States, 2001–2014. JAMA Psychiatry 2017 ; 74 : 747 – 755
36.
US Food and Drug Administration: FDA urges caution about withholding opioid addiction medications from patients taking benzodiazepines or CNS depressants: careful medication management can reduce risks. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-urges-caution-about-withholding-opioid-addiction-medications
37.
Mateu-Gelabert P, Jessell L, Goodbody E, et al : High enhancer, downer, withdrawal helper: Multifunctional nonmedical benzodiazepine use among young adult opioid users in New York City. Int J Drug Policy 2017 ; 46 : 17 – 27
38.
Wu LT, Anthony JC : The use of the case-crossover design in studying illicit drug use. Subst Use Misuse 2000 ; 35 : 1035 – 1050
39.
Maclure M, Mittleman MA : Should we use a case-crossover design? Annu Rev Public Health 2000 ; 21 : 193 – 221
Information & Authors
Information
Published In
History
Received: 6 August 2020
Revision received: 9 October 2020
Accepted: 2 November 2020
Published online: 3 March 2021
Published in print: July 2021
Keywords
Authors
Funding Information
Dr. Borodovsky serves on the board of directors of and as treasurer for MySafeRx. Dr. Bierut is listed as an inventor on a U.S. patent, “Markers for Addiction,” covering use of single-nucleotide polymorphisms in determining the diagnosis, prognosis, and treatment of addiction. The other authors report no financial relationships with commercial interests.Supported by NIH grant R25 MH112473-01 to Dr. Xu, grants R21 AA024888-01 and UL1 TR002345 to Dr. Hartz, grant R21 DA044744 to Drs. Hartz and Grucza, grants U10 AA008401 and R01 DA036583 to Dr. Bierut, grant K12 DA041449 to Dr. Mintz, and grants R21 AA02568901 and F32 AA027941 to Dr. Borodovsky.
Metrics & Citations
Metrics
Citations
Export Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
For more information or tips please see 'Downloading to a citation manager' in the Help menu.
View Options
View options
PDF/EPUB
View PDF/EPUBLogin options
Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.
Personal login Institutional Login Open Athens loginNot a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).